News - Pfizer, Anti-Arthritics/Rheumatics


Popular Filters

1 to 25 of 44 results

Pfizer’s tofacitinib meets primary endpoints in Ph III psoriasis study


US pharma giant Pfizer on Friday announced positive results from the Oral treatment Psoriasis Trial (OPT)…


Actavis settles Celebrex patent challenge with Pfizer


Ireland-headquartered generic major Actavis has entered into an agreement with US pharma giant Pfizer…


Teva and Pfizer settle patent litigation over Celebrex


Israel-based Teva Pharmaceutical Industries says that its US subsidiary has settled a law suit with US…

Anti-Arthritics/RheumaticsCelebrexGenericsNorth AmericaPatentsPfizerTeva Pharmaceutical IndustriesUSA

EMD Serono, Pfizer and Broad Institute link up on lupus research

EMD Serono, Pfizer and Broad Institute link up on lupus research


EMD Serono, a US subsidiary of Germany’s Merck KGaA, has signed a research agreement with US pharma…

Anti-Arthritics/RheumaticsEMD SeronoMerck KGaAPfizerPharmaceuticalResearch

Pfizer to appeal Court decision on Celebrex reissue patent

Pfizer to appeal Court decision on Celebrex reissue patent


US pharma behemoth Pfizer confirmed today that the US District Court for the Eastern District of Virginia…

Anti-Arthritics/RheumaticsCelebrexLegalNorth AmericaPatentsPfizerPharmaceuticalUSA

FDA advisory panel ambivalent on NSAID cardiovascular risk

FDA advisory panel ambivalent on NSAID cardiovascular risk


The US Food and Drug Administration’s joint Arthritis Advisory Committee and Drug Safety and Risk Management…

Anti-Arthritics/RheumaticsBayerNaproxenNeurologicalNorth AmericaPfizerPharmaceuticalUSA

European prescribing attitudes for rheumatoid arthritis post-ADACTA

European prescribing attitudes for rheumatoid arthritis post-ADACTA


Results from the ADACTA trial, which showed that Swiss drug major Roche’s RoActemra (tocilizumab) is…

AbbVieAnti-Arthritics/RheumaticsBiotechnologyEuropeHumiraMarkets & MarketingPfizerRoActemraRochetofactinib

Enbrel and Humira remain the mainstay for first-line biologic rheumatoid arthritis treatment in USA


The vast majority of patients in the USA treated with Amgen's (Nasdaq: AMGN) Enbrel (etanercept) and…

AbbVieAmgenAnti-Arthritics/RheumaticsEnbrelHumiraMarkets & MarketingNorth AmericaPfizerPharmaceuticalXeljanz

Karo Bio gets first milestone in Pfizer collaboration


Under its collaboration with US pharma behemoth Pfizer (NYSE: PFE), Sweden's Karo Bio (STO: KARO) says…

Anti-Arthritics/RheumaticsDermatologicalsFinancialKaro BioLicensingNeurologicalPfizerPharmaceuticalResearch

Disappointment for Pfizer on negative CHMP view for Xeljanz


There was disappointment for US pharma behemoth Pfizer (NNYSE: PFE), when the European Medicines Agency's…


Pfizer gets Swiss nod for Xeljanz for rheumatoid arthritis


US drug giant Pfizer (NYSE: PFE) said its rheumatoid arthritis (RA) therapy Xeljanz (tofacitinib) has…

Anti-Arthritics/RheumaticsEuropePfizerPharmaceuticalRegulationTakeda NycomedXeljanz

Bioventus in-licenses exclusive rights to Pfizer's BMP portfolio


USA-based orthopedic healing specialist Bioventus, a spin out from the UK's Smith & Nephew to an Essex…

Anti-Arthritics/RheumaticsBioventusGlobalhyaluronic acidLicensingPfizerPharmaceutical

Rise of rheumatoid arthritis therapies: JAK inhibitor battle and biosimilar threats


An approval of US drug major Eli Lilly (NYSE: LLY) and Incyte Pharmaceuticals'(Nasdaq: INCY) drug baricitinib…

Anti-Arthritics/RheumaticsbaricitinibBiotechnologyEli LillyIncyteMarkets & MarketingPfizerPharmaceuticalPricingXeljanz

Therapy's induction of remission an attribute that most influences Rxing decisions in rheumatoid arthritis


The majority of US and European rheumatologists surveyed by health care advisory firm Decision Resources…

AbbVieActemraAnti-Arthritics/RheumaticsEisaiEuropeHumiraMarkets & MarketingNorth AmericaPfizerPharmaceuticalRocheTakeda PharmaceuticalsXeljanz

Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors


Bazedoxifene, a drug approved in some countries to treat osteoporosis, has now been shown to stop the…


Arthritis drug disappointment: will fostamatinib's failure force pharma back to the drawing board?


Recent news of fostamatinib's latest failure to meet clinical endpoints marks yet another blow to an…

Anti-Arthritics/RheumaticsAstraZenecaBiotechnologyEli LillyfostamatinibPfizerPharmaceuticalRegulationResearchRigel PharmaceuticalstabalumabXeljanz

EMA committee gives thumbs down for Pfizer's Xeljanz for RA


Shares of Pfizer (NYSE: PFE) fell 2.4% to $29.53 in extended New York trading yesterday, after the pharma…


Mylan delivers "one pill once a day" ARV in South Africa; Cipla Debuts first Enbrel biosimilar


USA-based generic drugmaker Mylan (Nasdaq: MYL) says that it has delivered, through its South African-based…

AmgenAnti-Arthritics/RheumaticsAnti-viralsAsia-PacificBiotechnologyCiplaEnbrelEtaceptGenericsMarkets & MarketingMylan LaboratoriesPfizerRest of the World

BioTrends views Xeljanz and Zytiga prescribing in USA


After around two months on the market, 37% of US rheumatologists have prescribed Pfizer's (NYSE: PFE)…

Anti-Arthritics/RheumaticsAstellas PharmaBiotechnologyJevtanaJohnson & JohnsonMedivationNorth AmericaOncologyPfizerPharmaceuticalSanofiXeljanzXtandiZytiga

News briefs: Pfizer's filiburvir; Sanofi's Plavix; EMA sued over transparency


Among a batch of news reported over the weekend, US drugs behemoth Pfizer (NYSE: PFE) has halted development…

AbbVieAnti-Arthritics/RheumaticsAnti-viralsBiotechnologyCardio-vascularEuropefiliburvirHumiraInterMuneNorth AmericaPfizerPharmaceuticalPlavixRegulationResearchSanofi

USPTO grants Pfizer reissue patent for Celebrex, extending term to Dec 2015


Global pharma behemoth Pfizer (NYSE: PFE) said yesterday that the US Patent & Trademark Office has granted…

Anti-Arthritics/RheumaticsApotexCelebrexGenericsLupinMylan LaboratoriesNorth AmericaPatentsPfizerPharmaceuticalTeva Pharmaceutical IndustriesWatson Pharmaceuticals

1 to 25 of 44 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top